Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.43 |
| ▸ | CACNG8 | Q8WXS5 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679610 | 0.82 | TRPA1 (0.58) | TRPA1ABL1SCN9APOLBNPSR1 | |
| SCHEMBL13398286 | 0.78 | QPCT (0.46) | TRPA1NPSR1 | |
| SCHEMBL20320804 | 0.76 | RUNX1 (0.41) | TRPA1SCN9ANPSR1CYP2C9CYP3A4 | |
| SCHEMBL30109002 | 0.76 | RUNX1 (0.41) | TRPA1SCN9ANPSR1CYP2C9CYP3A4 | |
| SCHEMBL5512134 | 0.76 | DYRK3 (0.42) | NPSR1CYP3A4 | |
| SCHEMBL30026257 | 0.74 | TRPA1 (0.57) | TRPA1ABL1SCN9ACYP2C9CYP3A4 | |
| SCHEMBL3745835 | 0.74 | CYP3A4 (0.62) | TRPA1ABL1SCN9APOLBNPSR1 | |
| SCHEMBL1798963 | 0.74 | TRPV1 (0.57) | TRPA1 | |
| SCHEMBL1798959 | 0.74 | TRPV1 (0.57) | TRPA1 | |
| SCHEMBL2770465 | 0.74 | CYP3A4 (0.62) | TRPA1ABL1SCN9APOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349256-B1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| CN-102245181-A | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2011-11-16 | — | — | CN | disclosed |
| EP-2349256-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | Janssen Pharmaceutica NV (BE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010045166-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM6 | TRPA1 9/4885ABL1 1987/4885SCN9A 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.